In the current study, a positive correlation was found between high expression levels of glucose transporters (i.e., GLUT1, GLUT3, GLUT4, and SGLT1) and refractory to adjuvant FOLFOX chemotherapy in CRC patients. This evidence concerns the gene SLC2A1 and colorectal carcinoma.